News
OGEN
1.055
+4.46%
0.045
Weekly Report: what happened at OGEN last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at OGEN last week (0708-0712)?
Weekly Report · 07/15 09:34
Weekly Report: what happened at OGEN last week (0701-0705)?
Weekly Report · 07/08 09:34
Weekly Report: what happened at OGEN last week (0624-0628)?
Weekly Report · 07/01 09:34
Oragenics unveils automated intranasal device for treating concussed patients
Healthcare Oragenics unveils automated intranasal device for treating concussed patients. The breath-propelled device requires the patient to administer the drug into the nose. The company added that a phase II study is being designed to analyze the effectiveness of ONP-002.
Seeking Alpha · 06/27 12:59
Oragenics, Inc. Announces Closing of Public Offering
Oragenics, Inc. Is a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders. Oragenics announced the closing of its public offering of 1,100,000 shares of its common stock at $1.00 per share.
Barchart · 06/26 15:47
Oragenics prices public offering of common stock
Healthcare Oragenics prices public offering of common stock at $1.00 per share. The company intends to use the net proceeds from the offering to fund the development of its ONP-002 product candidate. The offering is expected to close on June 26, 2024.
Seeking Alpha · 06/25 13:43
Why Oragenics (OGEN) Shares Are Falling
Oragenics Inc (NASDAQ:OGEN) shares are trading lower by 21% to $1.03. The company announced a proposed public offering of 1.1 million shares of its common stock. The offering is expected to close around June 26. The funds will support the development of their ONP-002 product.
Benzinga · 06/25 13:26
Oragenics shares fall on proposed securities offering
Healthcare Oragenics shares fall on proposed securities offering. Shares of OGEN fell 6.02% in extended trading. OGEN plans to use the offering to fund the continued development of its ONP-002 product candidate. Oragenic, Inc. (OGEN) Stock.
Seeking Alpha · 06/25 05:52
Weekly Report: what happened at OGEN last week (0617-0621)?
Weekly Report · 06/24 09:36
Weekly Report: what happened at OGEN last week (0610-0614)?
Weekly Report · 06/17 09:34
Weekly Report: what happened at OGEN last week (0603-0607)?
Weekly Report · 06/10 09:34
12 Health Care Stocks Moving In Wednesday's After-Market Session
Anitra shares increased by 6.5% to $0.18 during Wednesday's after-market session. PACS Group (NYSE:PACS) shares rose 3.95% during the session. Oragenics (AMEX:OGEN) shares moved upwards by 4.24%. Losers include Concord Medical Services and Theriva Biologics.
Benzinga · 06/05 20:31
Weekly Report: what happened at OGEN last week (0527-0531)?
Weekly Report · 06/03 09:36
Weekly Report: what happened at OGEN last week (0520-0524)?
Weekly Report · 05/27 09:36
Nasdaq Falls Over 100 Points; TJX Posts Upbeat Q1 Results
The TJX Companies, Inc. Reported better-than-expected first-quarter financial results on Wednesday. Health care shares rose by on Wednesday; energy shares fell by 2%. The Nasdaq Composite fell over 100 points on Wednesday, with the Dow and S&P 500 also trading lower. Akoustis Technologies, Inc., shares shot up 127% after the company reported better than expected results.
Benzinga · 05/22 18:32
12 Health Care Stocks Moving In Wednesday's Intraday Session
IGM Biosciences shares increased by to $ during Wednesday's regular session. Akso Health Group stock moved upwards by $ during the session. Biodexa Pharmaceuticals shares declined by $ during the same period. LifeStance Health Gr (NASDAQ:LFST) shares decreased by $.
Benzinga · 05/22 16:31
Gold Down Over 1%; Williams-Sonoma Posts Strong Earnings
Stocks traded mixed midway through trading on Wednesday. The Dow traded down to 39, the NASDAQ rose to 16 and the S&P 500 fell to 5. Williams-Sonoma, Inc. Reported better-than-expected first-quarter earnings. Information technology shares rose by on Wednesday; energy shares fell. Asian markets closed mixed.
Benzinga · 05/22 16:17
CureVac, Oragenics, IGM Biosciences among healthcare movers
Seeking Alpha · 05/22 14:00
Press Release: Oragenics Appoints William "Frank" Peacock MD as Chief Clinical Officer
Dow Jones · 05/22 12:00
More
Webull provides a variety of real-time OGEN stock news. You can receive the latest news about Oragenics through multiple platforms. This information may help you make smarter investment decisions.
About OGEN
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.